Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors

Cancer Cell - United States
doi 10.1016/j.ccell.2014.08.017
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Ras-GTP Dimers Activate the Mitogen-Activated Protein Kinase (MAPK) Pathway

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2015English

Serum Response Factor Controls CYLD Expression via MAPK Signaling Pathway

PLoS ONE
Multidisciplinary
2011English

Relapsing Pneumonitis Due to Two Distinct Inhibitors of the MAPK/ERK Pathway: Report of a Case

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

TP53 Mutant Cell Lines Selected for Resistance to MDM2 Inhibitors Retain Growth Inhibition by MAPK Pathway Inhibitors but a Reduced Apoptotic Response

Cancer Cell International
Cancer ResearchOncologyGenetics
2019English

Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2019English

Bone Resorption in Syndromes of the Ras/Mapk Pathway

Clinical Genetics
Genetics
2011English

Naturally Occurring Mutations to HCV Protease Inhibitors in Treatment-Naïve Patients

Virology Journal
VirologyInfectious Diseases
2012English

The ERK MAPK Pathway in Bone and Cartilage Formation

2012English

Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma

Cancer Discovery
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy